GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca

GlaxoSmithKline has boosted its challenge for the anemia due to chronic kidney disease market, revealing a clean sweep of hits on key endpoints across two phase 3 clinical trials. But with the FDA rejecting AstraZeneca’s rival drug, doubts remain about GSK’s chances of getting to market.